7,732 Shares in DexCom, Inc. $DXCM Acquired by Inspire Advisors LLC

Inspire Advisors LLC bought a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 7,732 shares of the medical device company’s stock, valued at approximately $675,000.

Several other institutional investors and hedge funds have also bought and sold shares of DXCM. Andra AP fonden purchased a new stake in shares of DexCom during the 2nd quarter valued at $26,000. Zions Bancorporation National Association UT purchased a new position in DexCom during the 1st quarter worth $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in DexCom during the 2nd quarter valued at about $45,000. Anderson Financial Strategies LLC purchased a new stake in DexCom in the first quarter valued at about $37,000. Finally, Atlantic Union Bankshares Corp acquired a new stake in DexCom in the second quarter worth about $70,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Stock Up 2.9%

DXCM stock opened at $60.17 on Wednesday. The company has a market capitalization of $23.47 billion, a P/E ratio of 41.78, a price-to-earnings-growth ratio of 1.43 and a beta of 1.40. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $93.25. The firm’s fifty day simple moving average is $66.49 and its 200-day simple moving average is $77.02. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.04. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.18 billion. During the same period in the previous year, the firm posted $0.45 earnings per share. The firm’s quarterly revenue was up 21.6% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently issued reports on DXCM. Wall Street Zen downgraded shares of DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday. Citigroup cut their price target on shares of DexCom from $85.00 to $75.00 and set a “buy” rating on the stock in a research note on Friday, October 31st. Barclays set a $80.00 price target on shares of DexCom and gave the stock an “equal weight” rating in a report on Monday, November 3rd. Oppenheimer lowered shares of DexCom from an “outperform” rating to a “market perform” rating in a report on Monday, September 8th. Finally, UBS Group reduced their target price on DexCom from $106.00 to $95.00 and set a “buy” rating for the company in a research note on Monday, November 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $87.62.

Insiders Place Their Bets

In related news, EVP Sadie Stern sold 1,466 shares of DexCom stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $80.00, for a total transaction of $117,280.00. Following the completion of the transaction, the executive vice president directly owned 105,223 shares in the company, valued at approximately $8,417,840. This trade represents a 1.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bridgette P. Heller sold 1,012 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total value of $58,766.84. Following the completion of the sale, the director owned 27,031 shares in the company, valued at approximately $1,569,690.17. This represents a 3.61% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 9,999 shares of company stock worth $619,391. 0.32% of the stock is currently owned by company insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.